eras-801
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 25, 2022 (NCT05222802)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068579 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07089641 | Phase 1 | Jul 28, 2025 | University of California, Los Angeles |
| NCT06934889 | Phase 1 | Apr 7, 2025 | Memorial Sloan-Kettering Cancer Center |
| NCT05222802 | Phase 1 | Feb 25, 2022 | Erasca, Inc., Innovaderm |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Erasca, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Innovaderm | For profit | 1 | 0 | 1 | 2022 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1